The TRUTAKNA launch is the primary catalyst, not quarterly financials. Watch for ORIGIN 3 final efficacy data in Q3 2026 and sBLA submission in Q4 2026, which could drive full approval. The accelerating cash burn (doubled in H1 2026 vs H1 2025) makes the upcoming data readouts and potential financing events critical for near-term price action.
Price Chart
Executive Summary
Vera Therapeutics reported Q2 2026 net loss of $109.5M (-$1.52 EPS), wider than the $76.5M loss in Q2 2025 and a miss vs consensus (-$1.69 EPS implied by the Q1 context miss pattern vs -$1.59 consensus). The key positive is the FDA accelerated approval of TRUTAKNA and its early commercial launch in IgAN, offset by a cash burn of $206.8M in H1 2026 and no revenue yet.
Key Financial Metrics
Key Facts
- FDA accelerated approval of TRUTAKNA (atacicept-vymj) for IgAN, first BAFF/APRIL inhibitor approved
- U.S. commercial launch underway; early reception described as encouraging
- Q2 2026 net loss of $109.5M vs $76.5M in Q2 2025; operating expenses $112.5M vs $80.1M
- Net cash used in operating activities H1 2026: $206.8M vs $109.2M in H1 2025
- Cash and securities $499.2M at June 30, 2026 plus up to $425M debt facility
- Final ORIGIN 3 efficacy data expected Q3 2026; sBLA submission for full approval expected Q4 2026
- Potential full approval of TRUTAKNA in IgAN expected in 2027
Financial Impact
Q2 2026 net loss $109.5M (-$1.52 EPS) vs consensus miss pattern; cash burn of $206.8M in H1; no product revenue yet
Risk Factors
- Accelerating cash burn $206.8M in H1 2026 may necessitate dilutive financing before cash flow breakeven
- Full approval still contingent on ORIGIN 3 confirmatory trial; failure would limit revenue opportunity
- Commercial launch execution risk despite experienced team; no product revenue guidance provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access